LaNCE-Neuropharm: Laboratorio de Neurociencia Clínica y Experimental para el estudio farmacológico de la neuroprotección-neurodegeneración-neurorregeneración
University of Padua
Padua, ItaliaPublications en collaboration avec des chercheurs de University of Padua (3)
2021
-
Histamine H3 and H4 receptors modulate Parkinson's disease induced brain pathology. Neuroprotective effects of nanowired BF-2649 and clobenpropit with anti-histamine-antibody therapy
Progress in Brain Research (Elsevier B.V.), pp. 1-73
2018
-
Histamine H3 inverse agonist BF 2649 or antagonist with partial h4 agonist activity clobenpropit reduces amyloid beta peptide-induced brain pathology in alzheimer’s disease
Molecular Neurobiology, Vol. 55, Núm. 1, pp. 312-321
2016
-
Pathophysiology of blood-brain barrier in brain injury in cold and hot environments: Novel drug targets for neuroprotection
CNS and Neurological Disorders - Drug Targets, Vol. 15, Núm. 9, pp. 1045-1071